Target therapy of polycystic ovary syndrome
https://doi.org/10.21518/ms2023-060
Abstract
Due to the complexity of the diagnosis and treatment of polycystic ovary syndrome (PCOS) in adolescents, studies are currently underway to select targeted therapy to normalize the metabolic and reproductive status of girls, including those at risk for PCOS. There are a lot of researches, that evaluate the effectiveness of inositol therapy in PCOS, ovarian dysfunction, insulin resistance (IR), ovarian hyperandrogenism in both adolescents and adult women, including those in IVF cycles. Currently, the choice of determining the ratio of myo-inositol (MI) and d-chiro-inositol (DCI) for the treatment of PCOS often leads to the physiological proportion of inositols in plasma (40:1), since research results are insufficient to unambiguously confirm it. In this connection, there is a large number of pharmaceuticals without or with a low dosage of DCI, that can’t bypass the defective epimerase activity and achieve an adequate level of DCI in the ovaries. Determination of a fair assessment and dosage of MI/DCI is required for long-term correction of metabolic, endocrinological and clinical manifestations of various PCOS phenotypes. Inositols are promising and safe treatment of hyperandrogenism, obesity, insulin resistance in women of various age groups and can also effectively complement a therapeutic effect of metformin and combined oral contraceptives.
About the Authors
A. I. Turchinets
Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
Anna I. Turchinets, Postgraduate Student,
4, Academician Oparin St., Moscow, 117997
E. V. Uvarova
Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology;
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Elena V. Uvarova, Corr. Member RAS, Dr. Sci. (Med.), Professor, Head of the 2nd Gynecological Department, 4, Academician Oparin St., Moscow, 117997;
Professor of the Department of Obstetrics, Gynecology, Perinatology and Reproductology, Institute of Professional Education, 8, Bldg. 2, Trubetskaya St., Moscow, 119991;
President of the Interregional Public Organization “Association of Pediatric and Adolescent Gynecologists”
E. P. Khashchenko
Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
Elena P. Khashchenko, Senior Researcher, 2nd Gynecological Department,
4, Academician Oparin St., Moscow, 117997
Z. Kh. Kumykova
Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
Zaira Kh. Kumykova, Cand. Sci. (Med.), Senior Researcher, 2nd Gynecological Department (Gynecology of Pediatric and Adolescent Age),
4, Academician Oparin St., Moscow, 117997
References
1. Peña A.S., Codner E., Witchel S. Criteria for Diagnosis of Polycystic Ovary Syndrome during Adolescence: Literature Review. Diagnostics (Basel). 2022;12(8):1931. https://doi.org/10.3390/diagnostics12081931.
2. Khaschenko E.P., Uvarova E.V., Mamedova F.Sh. Phenotypic features of polycystic ovary syndrome in adolescent girls. Pediatric and Adolescent Reproductive Health. 2017;(1):37–50. (In Russ.) https://doi.org/10.24411/1816-2134-2017-00015.
3. Tay C.T., Hart R.J., Hickey M., Moran L.J., Earnest A., Doherty D.A. et al. Updated adolescent diagnostic criteria for polycystic ovary syndrome: impact on prevalence and longitudinal body mass index trajectories from birth to adulthood. BMC Med. 2020;18(1):389. https://doi.org/10.1186/s12916-020-01861-x.
4. Khashchenko E., Uvarova E., Vysokikh M., Ivanets T., Krechetova L., Tarasova N. et al. The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents. J Clin Med. 2020;9(6):1831. https://doi.org/10.3390/jcm9061831.
5. Adamyan L.V., Andreeva E.N., Absatarova Yu.S., Grigoryan O.R., Dedov I.I., Melnichenko G.A. et al. Polycystic ovary syndrome: clinical guidelines. Moscow; 2021. 57 p. (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/258_2.
6. Manique M.E.S., Ferreira A.M.A.P. Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management. Rev Bras Ginecol Obstet. 2022;44(4):425–433. https://doi.org/10.1055/s-0042-1742292.
7. Trent M., Gordon C.M. Diagnosis and Management of Polycystic Ovary Syndrome in Adolescents. Pediatrics. 2020;145(Suppl. 2):S210–S218. https://doi.org/10.1542/peds.2019-2056J.
8. Belova I.S., Khashchenko E.P., Uvarova E.V., Andreeva V.O. Psychoemotional status and eating disorders in the polycystic ovary syndrome pathogenesis among adolescence. Pediatric and Adolescent Reproductive Health. 2021;17(3):82–93. (In Russ.) https://doi.org/10.33029/1816-2134-2021-17-3-82-93.
9. Bhide P., Pundir J., Gudi A., Shah A., Homburg R., Acharya G. The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019;98(10):1235–1244. https://doi.org/10.1111/aogs.13625.
10. Kalra B., Kalra S., Sharma J.B. The inositols and polycystic ovary syndrome. Indian J Endocrinol Metab. 2016;20(5):720–724. https://doi.org/10.4103/2230- 8210.189231.
11. Russo M., Forte G., Montanino Oliva M., Laganà A.S., Unfer V. Melatonin and Myo-Inositol: Supporting Reproduction from the Oocyte to Birth. Int J Mol Sci. 2021;22(16):8433. https://doi.org/10.3390/ijms22168433.
12. Kamenov Z., Gateva A. Inositols in PCOS. Molecules. 2020;25(23):5566. https://doi.org/10.3390/molecules25235566.
13. Cabrera-Cruz H., Oróstica L., Plaza-Parrochia F., Torres-Pinto I., Romero C., Vega M. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. Am J Physiol Endocrinol Metab. 2020;318(2):E237–E248. https://doi.org/10.1152/ajpendo.00162.2019.
14. Bizzarri M., Fuso A., Dinicola S., Cucina A., Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol. 2016;12(10):1181–1196. https://doi.org/10.1080/17425255.2016.1206887.
15. Unfer V., Facchinetti F., Orrù B., Giordani B., Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–658. https://doi.org/10.1530/EC-17-0243.
16. Unfer V., Nestler J.E., Kamenov Z.A., Prapas N., Facchinetti F. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. Int J Endocrinol. 2016:1849162. https://doi.org/10.1155/2016/1849162.
17. Carlomagno G., Unfer V., Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95(8):2515–2516. https://doi.org/10.1016/j.fertnstert.2011.05.027.
18. Gromova O.A., Torshin I.Yu., Uvarova E.V., Tapilskaya N.I., Kalacheva A.G. Systematic analysis of the biological roles and pharmacological properties of D-chiro-inositol. Gynecology. 2020;22(3):21–28. (In Russ.) https://doi.org/10.26442/20795696.2020.3.200210.
19. Dobrokhotova Yu.E., Gromova O.A., Dukhanin A.S., Kumykova Z.Kh., Sheremetyeva E.V., Tabeeva G.I. Inositols: pharmacology and findings of clinical trials. Current evidence and prospects. Russian Journal of Woman and Child Health. 2022;5(4):309–319 (In Russ.) https://doi.org/10.32364/2618-8430-2022-5-4-309-319.
20. Facchinetti F., Orrù B., Grandi G., Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35(3):198–206. https://doi.org/10.1080/09513590.2018.1540578.
21. Goodarzi M.O., Korenman S.G. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril. 2003;80(2):255–258. https://doi.org/10.1016/s0015-0282(03)00734-9.
22. Prilutskaya V.Yu., Alyautdina O.S., Sosna N.A. The effect of the combination of myoinositol and D-chiroinositol in a ratio of 5:1 on the psychoemotional state and manifestations of androgen-dependent dermopathy in patients with polycystic ovary syndrome. Russian Journal of Human Reproduction. 2021;27(4):97–107. (In Russ.) https://doi.org/10.17116/repro20212704197.
23. Akbari Sene A., Tabatabaie A., Nikniaz H., Alizadeh A., Sheibani K., Mortezapour Alisaraie M. et al. The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial. Arch Gynecol Obstet. 2019;299(6):1701–1707. https://doi.org/10.1007/s00404-019-05111-1.
24. Showell M.G., Mackenzie-Proctor R., Jordan V., Hodgson R., Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;12(12):CD012378. https://doi.org/10.1002/14651858.CD012378.pub2.
25. Vartanyan E.V., Tsaturova K.A., Devyatova E.A., Mikhaylyukova A.S., Levin V.A., Petuhova N.L. et al. Improvement in quality of oocytes in polycystic ovarian syndrome in programs of in vitro fertilization. Gynecol Endocrinol. 2017;33(Suppl. 1):8–11. https://doi.org/10.1080/09513590.2017.1399699.
26. Regidor P.A., Schindler A.E., Lesoine B., Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm Mol Biol Clin Investig. 2018;34(2):2017-0067. https://doi.org/10.1515/hmbci-2017-0067.
27. Ciotta L., Stracquadanio M., Pagano I., Carbonaro A., Palumbo M., Gulino F. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci. 2011;15(5):509–514. Available at: https://www.europeanreview.org/wp/wp-content/uploads/938.pdf.
28. Brusco G.F., Mariani M. Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci. 2013;17(22):3095–3102. Available at: https://www.europeanreview.org/wp/wp-content/uploads/3095-3102.pdf.
29. Deo S., Pandey K., Kumari P., Deo N. Effectiveness of Myo-Inositol and Combined Oral Contraceptives in Adolescent and Young Women with PCOS. SSR Inst Int J Life Sci. 2021;7(2):2763–2773. https://doi.org/10.21276/SSR-IIJLS.2021.7.2.1.
30. Pkhaladze L., Barbakadze L., Kvashilava N. Myo-Inositol in the Treatment of Teenagers Affected by PCOS. Int J Endocrinol. 2016;2016:1473612. https://doi.org/10.1155/2016/1473612.
31. Greff D., Juhász A.E., Váncsa S., Váradi A., Sipos Z., Szinte J. et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023;21(1):10. https://doi.org/10.1186/s12958-023-01055-z.
32. Larner J. D-chiro-inositol its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3(1):47–60. https://doi.org/10.1080/15604280212528.
33. Artini P.G., Di Berardino O.M., Papini F., Genazzani A.D., Simi G., Ruggiero M., Cela V. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013;29(4):375–379. https://doi.org/10.3109/09513590.2012.743020.
34. La Marca A., Grisendi V., Dondi G., Sighinolfi G., Cianci A. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol. 2015;31(1):52–56. https://doi.org/10.3109/09513590.2014.964201.
35. Piomboni P., Focarelli R., Capaldo A., Stendardi A., Cappelli V., Cianci A. et al. Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J Assist Reprod Genet. 2014;31(10):1269–1276. https://doi.org/10.1007/s10815-014-0307-z.
36. Ashraf A., Kundi M.B., Arif S.U., Asif M., Ilyas M., Rehan H. Analysis of D-Chiro inositol in lowering androgen levels in PCOS patients. Research Square. 2022. https://doi.org/10.21203/rs.3.rs-1329990/v1.
37. Laganà A.S., Barbaro L., Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet. 2015;291(5):1181–1186. https://doi.org/10.1007/s00404-014-3552-6.
38. Nordio M., Bezerra Espinola M.S., Bilotta G., Capoccia E., Montanino Oliva M. Long-Lasting Therapies with High Doses of D-chiro-inositol: The Downside. J Clin Med. 2023;12(1):390. https://doi.org/10.3390/jcm12010390.
39. Minozzi M., D’Andrea G., Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online. 2008;17(4):579–582. https://doi.org/10.1016/s1472-6483(10)60248-9.
40. Thalamati S. A comparative study of combination of Myo-inositol and D-chiroinositol versus Metformin in the management of polycystic ovary syndrome in obese women with infertility. Int J Reprod Contracept Obstet Gynecol. 2019;8(3):825–829. https://doi.org/10.18203/2320-1770.ijrcog20190498.
41. Baillargeon J.P., Iuorno M.J., Jakubowicz D.J., Apridonidze T., He N., Nestler J.E. Metformin therapy increases insulin-stimulated release of D-chiro-inositolcontaining inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(1):242–249. https://doi.org/10.1210/jc.2003-030437.
42. Nordio M., Proietti E. The combined therapy with myo-inositol and D-chiroinositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012;16(5):575–581. Available at: https://www.europeanreview.org/wp/wp-content/uploads/1357.pdf.
43. Minozzi M., Nordio M., Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013;17(4):537–540. Available at: https://www.europeanreview.org/wp/ wp-content/uploads/537-540.pdf.
44. Colazingari S., Treglia M., Najjar R., Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288(6):1405–1411. https://doi.org/10.1007/s00404-013-2855-3.
45. Januszewski M., Issat T., Jakimiuk A.A., Santor-Zaczynska M., Jakimiuk A.J. Metabolic and hormonal effects of a combined Myo-inositol and d-chiroinositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol. 2019;90(1):7–10. https://doi.org/10.5603/GP.2019.0002.
46. Mendoza N., Diaz-Ropero M.P., Aragon M., Maldonado V., Llaneza P., Lorente J. et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019;35(8):695–700. https://doi.org/10.1080/09513590.2019.1576620.
47. Mendoza N., Galan M.I., Molina C., Mendoza-Tesarik R., Conde C., Mazheika M. et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2020;36(5):398–401. https://doi.org/10.1080/09513590.2019.1681959.
Review
For citations:
Turchinets AI, Uvarova EV, Khashchenko EP, Kumykova ZK. Target therapy of polycystic ovary syndrome. Meditsinskiy sovet = Medical Council. 2023;(5):7-13. (In Russ.) https://doi.org/10.21518/ms2023-060
Views:
586
Email this article 